Kevin C Soares
Overview
Explore the profile of Kevin C Soares including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
1779
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sethna Z, Guasp P, Reiche C, Milighetti M, Ceglia N, Patterson E, et al.
Nature
. 2025 Feb;
PMID: 39972124
A fundamental challenge for cancer vaccines is to generate long-lived functional T cells that are specific for tumour antigens. Here we find that mRNA-lipoplex vaccines against somatic mutation-derived neoantigens may...
2.
McMillan M, Soares K
J Gastrointest Cancer
. 2025 Feb;
56(1):62.
PMID: 39939414
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal cancers, with a 5-year survival rate that has improved only marginally over the past 30 years, despite numerous clinical trials....
3.
Schleimer L, Liu A, Kalvin H, Barekzai A, Choubey A, Jung J, et al.
Ann Surg Oncol
. 2025 Jan;
PMID: 39875717
Background: A growing number of centers offer hepatic artery infusion pump (HAIP) chemotherapy for advanced liver malignancies. While small series have demonstrated feasibility of robotic HAIP placement, comparison of outcomes...
4.
Eikenboom E, Nasar N, Seier K, Gonen M, Spaander M, OReilly E, et al.
Ann Surg Oncol
. 2025 Jan;
PMID: 39873847
No abstract available.
5.
Sharib J, Rhodin K, Liu A, McIntyre S, Bartholomew A, Masoud S, et al.
Ann Surg Oncol
. 2025 Jan;
32(4):2501-2502.
PMID: 39873846
No abstract available.
6.
Sharib J, Rhodin K, Liu A, McIntyre S, Bartholomew A, Masoud S, et al.
Ann Surg Oncol
. 2025 Jan;
32(4):2456-2466.
PMID: 39827317
Background: Randomized data suggest improved survival with adjuvant chemotherapy for biliary tract cancers; however, subset analyses of intrahepatic cholangiocarcinoma (IHC) show limited survival benefit. This study evaluated the impact of...
7.
Schleimer L, Aviki E, Kalvin H, Magnin J, Sokolowski S, Kingham T, et al.
JCO Oncol Pract
. 2024 Dec;
:OP2400528.
PMID: 39705655
Purpose: Financial toxicity (FT) is increasingly recognized as a major issue in cancer care. We evaluated the prevalence and risk factors for FT in patients with pancreatic ductal adenocarcinoma (PDAC)...
8.
Schleimer L, Hakki L, Seier K, Seo S, Cohen N, Usiak S, et al.
Ann Surg Oncol
. 2024 Dec;
32(4):2505-2506.
PMID: 39692984
No abstract available.
9.
Eikenboom E, Nasar N, Seier K, Gonen M, Spaander M, OReilly E, et al.
Ann Surg Oncol
. 2024 Dec;
PMID: 39656390
Background: Pancreatic ductal adenocarcinoma (PDAC) remains a challenging disease due to its aggressiveness, late-stage diagnosis, and limited treatment options. Microsatellite instability-high (MSI-H) cancers are susceptible to immune checkpoint inhibitors. Survival...
10.